Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC).

We are committed to providing relevant, accurate and timely information to investors and the financial community. Orphazyme is listed on Nasdaq Copenhagen (ORPHA) and Nasdaq US (ORPH).